

AMENDMENTS TO THE CLAIMS

The following list of claims replaces all prior versions and lists of claims:

We claim:

Claim 1 (Original): A method of treating systemic lupus erythematosus (SLE) in an individual, comprising administering to the individual an effective amount of an agent which reduces anti-dsDNA antibody in the individual, wherein the administration of the agent results in a sustained reduction of anti-dsDNA antibody, wherein the sustained reduction is at least about 10% below baseline in the individual, and wherein the individual is human.

Claim 2 (Original): The method of claim 1, wherein the agent comprises a dsDNA epitope which specifically binds to an anti-dsDNA antibody from the individual.

Claim 3 (Original): The method of claim 2, wherein the dsDNA epitope is a polynucleotide.


Claim 4 (Original): The method of claim 3, wherein the polynucleotide is DNA.

Claim 5 (Original): The method of claim 1, wherein the agent comprises a conjugate comprising a carrier and one or more double stranded DNA (dsDNA) epitopes, wherein the double stranded DNA epitopes are polynucleotides.

Claim 6 (Original): The method of claim 1, wherein the agent comprises a conjugate comprising a non-immunogenic valency platform molecule and two or more double stranded DNA (dsDNA) epitopes, wherein the double stranded DNA epitopes are polynucleotides.

Claim 7 (Currently Amended): The method of claim 5 or claim 6, wherein said polynucleotide comprises the sequence 5'-GTGTGTGTGTGTGTGT-3' (SEQ ID NO:1) and its complement.

Claim 8 (Original): The method of claim 7, wherein the platform molecule is



wherein PN is the polynucleotide.

Claim 9 (Original): The method of claim 7, wherein apparent equilibrium dissociation constant (K_D') for the polynucleotide with respect to the antibody from the individual before or upon initiation of treatment is less than or equal to about 0.8 mg IgG per ml.

Claim 10 (Original): The method of claim 1, wherein the sustained reduction is at least about 20% below baseline in the individual.

Claim 11 (Original): The method of claim 1, wherein the sustained reduction is at least about 30% below baseline in the individual.

Claim 12 (Original): The method of claim 1, wherein the sustained reduction is for at least about four months.

Claim 13 (Original): The method of claim 1, wherein the sustained reduction is for at least about one year.

Claim 14 (Original): A method of reducing risk of renal flare in an individual with systemic lupus erythematosus, comprising reducing the levels of anti-dsDNA antibodies in the individual by administering an effective amount of an agent which reduces anti-dsDNA antibody in the individual, and maintaining sustained reduction of the anti-dsDNA antibodies, wherein the

sustained reduction is at least about 10% below baseline in the individual, and wherein the individual is human.

Claim 15 (Original): The method of claim 14, wherein the agent comprises a dsDNA epitope which specifically binds to an anti-dsDNA antibody from the individual.

Claim 16 (Original): The method of claim 15, wherein the dsDNA epitope is a polynucleotide.


Claim 17 (Original): The method of claim 16, wherein the polynucleotide is DNA.

Claim 18 (Original): The method of claim 14, wherein the agent comprises a conjugate comprising a carrier and one or more double stranded DNA (dsDNA) epitopes, wherein the double stranded DNA epitopes are polynucleotides.

Claim 19 (Original): The method of claim 14, wherein the agent comprises a conjugate comprising a non-immunogenic valency platform molecule and two or more double stranded DNA (dsDNA) epitopes, wherein the double stranded DNA epitopes are polynucleotides.

Claim 20 (Currently Amended): The method of claim 18 or claim 19, wherein said polynucleotide comprises the sequence 5'-GTGTGTGTGTGTGTGTGT-3' (SEQ ID NO:1) and its complement.

Claim 21 (Original): The method of claim 20, wherein the platform molecule is



wherein PN is the polynucleotide.

Claim 22 (Original): The method of claim 20, wherein apparent equilibrium dissociation constant (K_D') for the polynucleotide with respect to the antibody from the individual before or upon initiation of treatment is less than or equal to about 0.8 mg IgG per ml.

Claim 23 (Original): The method of claim 14, wherein the sustained reduction is at least about 20% below baseline in the individual.

Claim 24 (Original): The method of claim 14, wherein the sustained reduction is at least about 30% below baseline in the individual.

Claim 25 (Original): The method of claim 14, wherein the sustained reduction is for at least about four months.

Claim 26 (Original): The method of claim 14, wherein the sustained reduction is for at least about one year.